Multicenter experience: Prevention and management of left ventricular assist device infections

被引:72
|
作者
Chinn, R
Dembitsky, W
Eaton, L
Chillcott, S
Stahovich, M
Rasmusson, B
Pagani, F
机构
[1] Sharp Mem Hosp & Rehabil Ctr, San Diego, CA USA
[2] Thoratec Corp, Pleasanton, CA USA
[3] LDS Hosp, Salt Lake City, UT USA
[4] Univ Michigan, Sect Cardiac Surg, Ann Arbor, MI 48109 USA
关键词
D O I
10.1097/01.mat.0000170620.65279.aa
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Implantable left ventricular assist devices (LVADs) have demonstrated clinical success in both the bridge-to-transplantation and destination-therapy patient populations; however, infection remains one of the most common causes of mortality during mechanical circulatory support. Thus, serious LVAD infections may negate the benefits of LVAD implantation, resulting in decreased quality of life, increased morbidity and mortality, and increased costs associated with implantation. Prevention of device-related infection is crucial to the cost-effective use of mechanical circulatory support devices. Therefore, adherence to evidence-based infection control and prevention guidelines, meticulous surgical technique and optimal postoperative surgical site care form the foundation for LVAD associated infection prevention.
引用
收藏
页码:461 / 470
页数:10
相关论文
共 50 条
  • [31] The Impact of Left Ventricular Assist Device Infections on Clinical Outcomes
    Harris, C. E.
    Coakley, L.
    Zhou, G.
    Frankel, K.
    Matiello, E.
    Melanson, F.
    Montoya, K.
    Hickey, M.
    Kim, A.
    Rinewalt, D. E.
    Givertz, M.
    Stewart, G. C.
    Mallidi, H. R.
    Mehra, M. R.
    Baden, L. R.
    Woolley, A. E.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2022, 41 (04): : S283 - S283
  • [32] Driveline Infections after Implantation of a Left Ventricular Assist Device
    Vandersmissen, K.
    Roppe, M.
    Droogne, W.
    Jacobs, S.
    Meyns, B.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2021, 40 (04): : S394 - S394
  • [33] Experience with dalbavancin for long-term antimicrobial suppression of left ventricular assist device infections
    Mansoor, Armaghan-e-Rehman
    Krekel, Tamara
    Cabrera, Nicolo L.
    TRANSPLANT INFECTIOUS DISEASE, 2023, 25 (04)
  • [34] LEFT VENTRICULAR ASSIST DEVICE INFECTIONS: A NEW ROLE FOR DALBAVANCIN?
    Howard-Anderson, J.
    Pouch, S.
    Sexton, M.
    Mehta, A.
    Cole, R.
    Lyon, G. M.
    Friedman-Moraco, R.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2019, 67 (02) : 457 - 457
  • [35] Cutaneous Fungal Infections in Left Ventricular Assist Device Recipients
    Jellyana Peraza
    Yoram A. Puius
    Current Fungal Infection Reports, 2020, 14 : 225 - 232
  • [36] Cutaneous Fungal Infections in Left Ventricular Assist Device Recipients
    Peraza, Jellyana
    Puius, Yoram A.
    CURRENT FUNGAL INFECTION REPORTS, 2020, 14 (03) : 225 - 232
  • [37] Multicenter experience with the Thoratec ventricular assist device in children and adolescents
    Reinhartz, O
    Keith, FM
    El-Banayosy, A
    McBride, LR
    Robbins, RC
    Copeland, JG
    Farrar, DJ
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2001, 20 (04): : 439 - 448
  • [38] Perioperative management of the left ventricular assist device recipient
    Heath, MJS
    Dickstein, ML
    PROGRESS IN CARDIOVASCULAR DISEASES, 2000, 43 (01) : 47 - 54
  • [39] Medication management for left ventricular assist device thrombosis
    Hohner, Elizabeth
    Crow, Jessica
    Moranville, Michael P.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2015, 72 (13) : 1104 - 1113
  • [40] Left Ventricular Assist Device: Indications, Management, and Complications
    Hamdan, A.
    Ortuno, S.
    Guerot, E.
    Aissaoui, N.
    MEDECINE INTENSIVE REANIMATION, 2019, 28 (02): : 96 - 102